These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26395652)

  • 1. Decisions Regarding Whether to Use Androgen Deprivation Therapy with Radiotherapy in Prostate Cancer: Is Cardiovascular Mortality the Most Relevant Outcome?
    Chen RC
    Eur Urol; 2016 Feb; 69(2):211-2. PubMed ID: 26395652
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply from Authors re: Ronald C. Chen. Decisions Regarding Whether to Use Androgen Deprivation Therapy with Radiotherapy in Prostate Cancer: Is Cardiovascular Mortality the Most Relevant Outcome? Eur Urol 2016;69:211-2: Outcomes for Favorable and Unfavorable Intermediate Risk Prostate Cancer Patients Receiving Radiation Therapy With or Without Short-term Androgen Deprivation Therapy.
    Voog JC; Paulus R; Efstathiou JA
    Eur Urol; 2016 Feb; 69(2):212-3. PubMed ID: 26443430
    [No Abstract]   [Full Text] [Related]  

  • 3. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.
    Jin C; Fan Y; Meng Y; Shen C; Wang Y; Hu S; Cui C; Xu T; Yu W; Jin J
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):333-339. PubMed ID: 27595915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
    Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
    Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
    Froehner M
    Cancer; 2011 Jun; 117(11):2577; author reply 2577-8. PubMed ID: 24048805
    [No Abstract]   [Full Text] [Related]  

  • 7. [Combined radiation therapy and androgen deprivation in the management of prostate cancer: Where do we stand?].
    Bellefqih S; Hadadi K; Mezouri I; Maghous A; Marnouche E; Andaloussi K; Elmarjany M; Sifat H; Mansouri H; Benjaafar N
    Cancer Radiother; 2016 Apr; 20(2):141-50. PubMed ID: 26969245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
    Madlung A; Simcock M; Ghadjar P
    Cancer; 2011 Aug; 117(15):3532; author reply 3532-3. PubMed ID: 21287542
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
    Walsh PC
    J Urol; 2011 Jan; 185(1):141. PubMed ID: 22082921
    [No Abstract]   [Full Text] [Related]  

  • 10. Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer.
    Krauss D; Kestin L; Ye H; Brabbins D; Ghilezan M; Gustafson G; Vicini F; Martinez A
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1064-71. PubMed ID: 20584576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era.
    D'Angelillo RM; Franco P; De Bari B; Fiorentino A; Arcangeli S; Alongi F
    Crit Rev Oncol Hematol; 2015 Feb; 93(2):136-48. PubMed ID: 25459667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Heavy ion radiotherapy for prostate cancer -- the role of hormone therapy].
    Suzuki K; Matsui H; Kawamura H; Ohno T
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):159-63. PubMed ID: 25743135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.
    Akakura K; Tsuji H; Suzuki H; Ichikawa T; Ishikawa H; Okada T; Kamada T; Harada M; Tsujii H; Shimazaki J
    Jpn J Clin Oncol; 2014 Apr; 44(4):360-5. PubMed ID: 24585931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cancer of the prostate: importance of androgen deprivation and radiotherapy].
    Rentsch CA; Aebersold DM; Merz V; Studer UE
    Rev Med Suisse; 2005 May; 1(19):1303-6. PubMed ID: 15962630
    [No Abstract]   [Full Text] [Related]  

  • 15. Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy.
    Morgans AK; Fan KH; Koyama T; Albertsen PC; Goodman M; Hamilton AS; Hoffman RM; Stanford JL; Stroup AM; Resnick MJ; Barocas DA; Penson DF
    J Urol; 2015 Apr; 193(4):1226-31. PubMed ID: 25451829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation therapy in high-risk prostate cancer.
    Buyyounouski MK
    Oncology (Williston Park); 2010 Aug; 24(9):806, 809. PubMed ID: 20923033
    [No Abstract]   [Full Text] [Related]  

  • 17. [Radiotherapy with androgen deprivation for localized prostate cancer].
    Yoshida K; Miyawaki D; Shimizu Y; Nishikawa R; Sasaki R
    Nihon Rinsho; 2016 May; 74 Suppl 3():503-7. PubMed ID: 27344783
    [No Abstract]   [Full Text] [Related]  

  • 18. Controversies in the treatment of prostate cancer with maximal androgen deprivation.
    McLeod DG; Moul JW
    Surg Oncol Clin N Am; 1995 Apr; 4(2):345-59. PubMed ID: 7796290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of radiation and androgen deprivation therapy for advanced prostate cancer.
    Jani AB; Rossi PJ
    Curr Probl Cancer; 2015; 39(1):41-7. PubMed ID: 25554467
    [No Abstract]   [Full Text] [Related]  

  • 20. Radiotherapy and androgen deprivation for prostate cancer.
    Créhange G; Bolla M; Maingon P
    N Engl J Med; 2011 Oct; 365(14):1354; author reply 1354-5. PubMed ID: 21991967
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.